Plus Therapeutics’ (PSTV) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report released on Thursday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright decreased their target price on Plus Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. D Boral Capital upgraded Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 3rd. Zacks Research cut Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Ascendiant Capital Markets lifted their price target on shares of Plus Therapeutics from $20.50 to $21.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Plus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Plus Therapeutics Trading Down 0.3%

Shares of PSTV stock opened at $0.49 on Thursday. The firm has a market capitalization of $67.12 million, a P/E ratio of -0.22 and a beta of 0.77. Plus Therapeutics has a 1 year low of $0.16 and a 1 year high of $2.31. The firm’s fifty day simple moving average is $0.58 and its 200 day simple moving average is $0.48.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The business had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.50 million. Equities research analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PSTV. Virtu Financial LLC bought a new stake in shares of Plus Therapeutics in the 1st quarter worth about $38,000. Jane Street Group LLC acquired a new position in Plus Therapeutics in the second quarter valued at about $41,000. Altium Capital Management LLC bought a new stake in Plus Therapeutics during the third quarter worth about $628,000. Scientech Research LLC bought a new stake in Plus Therapeutics during the third quarter worth about $100,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics during the third quarter worth approximately $46,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.